AGL 5.27 Decreased By ▼ -0.23 (-4.18%)
ANL 8.45 Decreased By ▼ -0.04 (-0.47%)
AVN 75.82 Increased By ▲ 0.02 (0.03%)
BOP 5.15 Decreased By ▼ -0.09 (-1.72%)
CNERGY 4.41 Decreased By ▼ -0.01 (-0.23%)
EFERT 81.30 Decreased By ▼ -0.33 (-0.4%)
EPCL 49.29 Decreased By ▼ -0.41 (-0.82%)
FCCL 12.40 Decreased By ▼ -0.39 (-3.05%)
FFL 5.51 Increased By ▲ 0.01 (0.18%)
FLYNG 6.82 Increased By ▲ 0.09 (1.34%)
FNEL 4.68 Decreased By ▼ -0.02 (-0.43%)
GGGL 9.27 Increased By ▲ 0.85 (10.1%)
GGL 14.88 Increased By ▲ 0.93 (6.67%)
HUMNL 6.18 Increased By ▲ 0.10 (1.64%)
KEL 2.57 Increased By ▲ 0.01 (0.39%)
LOTCHEM 27.73 Increased By ▲ 0.08 (0.29%)
MLCF 23.57 Decreased By ▼ -0.22 (-0.92%)
OGDC 71.91 Increased By ▲ 0.81 (1.14%)
PAEL 15.13 Increased By ▲ 0.10 (0.67%)
PIBTL 4.83 Decreased By ▼ -0.07 (-1.43%)
PRL 15.66 Decreased By ▼ -0.32 (-2%)
SILK 1.07 Decreased By ▼ -0.03 (-2.73%)
TELE 8.85 Increased By ▲ 0.03 (0.34%)
TPL 7.34 Increased By ▲ 0.26 (3.67%)
TPLP 19.49 Increased By ▲ 0.23 (1.19%)
TREET 21.08 Increased By ▲ 0.23 (1.1%)
TRG 137.25 Increased By ▲ 0.65 (0.48%)
UNITY 16.30 Decreased By ▼ -0.25 (-1.51%)
WAVES 9.35 Increased By ▲ 0.10 (1.08%)
WTL 1.38 Increased By ▲ 0.03 (2.22%)
BR100 4,164 Increased By 6.3 (0.15%)
BR30 15,350 Increased By 10.3 (0.07%)
KSE100 41,698 Increased By 46.7 (0.11%)
KSE30 15,402 Increased By 22.3 (0.15%)
World

China approves second domestic Covid-19 vaccine

  • Chinese vaccine makers also have chequered reputations, after major scandals at home involving expired or poor quality products.
Published February 6, 2021
Follow us

BEIJING: China's drug authorities have given "conditional" approval for a second Covid-19 vaccine, Sinovac's CoronaVac jab, the pharmaceutical company said Saturday.

The vaccine has already been rolled out to key groups at higher risk of exposure to coronavirus but Saturday's approval allows for its use on the general public.

A conditional approval helps hustle emergency drugs to market in cases when clinical trials are yet to meet normal standards but indicate therapies will work.

The approval comes after multiple domestic and overseas trials of the vaccine in countries including Brazil and Turkey, although "efficacy and safety results need to be further confirmed", Sinovac said in a statement.

Fellow Chinese pharmaceutical company Sinopharm received a similar conditional green light in December to put its vaccine on the market.

Sinovac said trials in Brazil had shown around 50 percent efficacy in preventing infection and 80 percent efficacy in preventing cases requiring medical intervention.

"The results show that the vaccine has good safety and immunogenic effect on people of all age groups," Sinovac said Saturday.

Meanwhile Sinopharm said in December that its vaccine had a 79.34 percent efficacy rate, lower than rival jabs developed in the West by Pfizer-BioNTech and Moderna -- with 95 and 94 percent rates respectively.

China has been racing to develop homegrown jabs and aims to vaccinate 50 million people before the start of the Lunar New Year in mid-February.

The holiday normally spurs a travel rush with hundreds of millions traversing the country -- though authorities are encouraging people to stay home this year through a mixture of restrictions and incentives.

As China ramps up its vaccine campaign, authorities have repeatedly assured the public of the jab's safety and efficacy, despite not releasing any detailed clinical trial data.

At the same time, Beijing has been promoting its vaccines abroad in what analysts have called "vaccine diplomacy" to earn goodwill after facing criticism for its early handling of the outbreak.

China's foreign ministry on Wednesday said it planned to provide 10 million vaccine doses to the WHO-backed international vaccine distribution programme Covax.

Beijing has also pledged to share the vaccine at a fair cost -- a potential boost for poorer Asian countries who are otherwise reliant on limited distribution offered by the Covax scheme.

Countries including Senegal, Indonesia, and Hungary have procured millions of vaccine doses from Chinese pharmaceutical firms.

But take-up has been slower abroad for Chinese vaccines compared to jabs from Pfizer-BioNTech and Moderna, as little information has been published about the safety or efficacy of Chinese vaccines.

Chinese vaccine makers also have chequered reputations, after major scandals at home involving expired or poor quality products.

Comments

Comments are closed.

China approves second domestic Covid-19 vaccine

Economy: Dar, others take stock of situation

Weekly SPI inflation unchanged on average

Xi calls for oil trade in yuan

Unilateral hike in rates of SEZs’ plots disallowed

FTO orders FBR to release soybean consignments

Russia could cut oil production over West’s ‘stupid’ price cap

Oil rebounds, but still on track for biggest weekly declines

ECs: SBP further tightening data reporting mechanism

Wapda asked to shift troops from Dasu hospital

Matters adjudicated by courts: FBR maintains no data bank